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Abstract
Background
Despite concerns about the representativeness of patients from ALS tertiary centers as
compared to the ALS general population, the extent of referral bias in clinical studies
remains largely unknown. Using data from EURALS consortium we aimed to assess nature,
extent and impact of referral bias.
Methods
Four European ALS population-based registries located in Ireland, Piedmont, Puglia, Italy,
and Limousin, France, covering 50 million person-years, participated. Demographic and
clinic characteristics of ALS patients diagnosed in tertiary referral centers were contrasted
with the whole ALS populations enrolled in registries in the same geographical areas.
Results
Patients referred to ALS centers were younger (with difference ranging from 1.1 years to 2.4
years), less likely to present a bulbar onset, with a higher proportion of familial antecedents
and a longer survival (ranging from 11% to 15%) when compared to the entire ALS popula-
tion in the same geographic area.
Conclusions
A trend for referral bias is present in cohorts drawn from ALS referral centers. The magni-
tude of the possible referral bias in a particular tertiary center can be estimated through a
comparison with ALS patients drawn from registry in the same geographic area. Studies
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based on clinical cohorts should be cautiously interpreted. The presence of a registry in the
same area may improve the complete ascertainment in the referral center.
Introduction
Data collected in amyotrophic lateral sclerosis (ALS) tertiary centers are used for descriptive
and analytic studies[1, 2], clinical investigations [3] including the construction of clinical prac-
tice guidelines [4, 5], randomized clinical trials (RCTs) and other scientific fields like medico-
economics [6]. Nevertheless, the investigation of this rare neurodegenerative disease (crude
incidence estimated at 2.16/100 000 person-years in Europe [7]) may be reliably quantified
only by population-based approach.
Tertiary-based cohort studies have been described as not representative of the true ALS
population due to incomplete case ascertainment related to a selection bias known as referral
bias [8]. Selection bias is a systematic error in the recruitment process determined by sampling,
non-response or loss to follow-up. Referral bias is a specific type of selection bias that deter-
mines a real sample different from the target study population in key variables [9].
Referral may also bias the inception of subjects in RCTs, as most clinical studies enrol
patients exclusively from ALS tertiary centers. Despite these concerns, the extent of referral
bias in studies remains largely unknown.
Several epidemiological registers have been established in Europe to accurately quantify the
incidence and clinical features of ALS in the general population using multiple sources of
information to ensure complete case ascertainment [10–18]. Using data from four European
ALS registry members of the EURALS consortium (pan-European ALS Register) we aimed (i)
to measure the extent of referral bias by comparing clinical, demographic features and survival
of population-based cohorts with ALS referral cohorts from the same population, (ii) to inves-
tigate variation in the extent of bias depending on settings and time.
Methods
Settings
Data for this study were obtained from four European ALS registries located in Piedmont
(PARALS), in Northern Italy, covering 4 225 023 inhabitants in 2 000 [11]; Puglia (SLAP), in
Southern Italy, covering 4,034,132 inhabitants in 2 000 [13]; Republic of Ireland (Irish ALS
register), covering 3 626 087 inhabitants in 1996 [10]; Limousin (FRALim), center of France,
covering 741 083 inhabitants in 2011 [14].
Time periods covered in Italian or Irish registers (prior to the year 2 000), were different
from the Limousin register (after the year 2000). This allowed us to examine possible evolution
over time of ALS demographic characteristics and the possible impact on referral.
In the study period, the total amount of person-years considered here is around 50 million.
Inclusion criteria
Patients were included (i) if they originated from the geographically defined catchment popu-
lations at the time of diagnosis of ALS according to (ii) the original El Escorial criteria (EEDC)
[19] (i.e. definite, probable, possible or suspected ALS) for PARALS, SLAP, and Irish ALS reg-
ister, or according to the revised EEDC [20] (i.e. definite, probable, probable laboratory-
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supported or possible ALS) for FRALim register, and then (iii) if they were identified by at
least one of the multiple sources used for case ascertainment.
Sources of case ascertainment
Multiple sources of ascertainment of cases are described in Table 1. In all cases, registers relied
on recruitment by ALS tertiary referral center, neurologists and neurophysiologists, both pri-
vate and from the national health system, in the geographic area of interest. Hospital discharge
data were considered by three registers, while local charitable associations, general practition-
ers or other specialists in the field were used in some cases.
Description of data available for each patient
The following information was available for each patient: age at diagnosis (years), family his-
tory of ALS (fALS), sex, site of symptom onset (defined as bulbar-onset, limb-onset, general-
ized, respiratory-onset),diagnostic delay (from date of symptom onset to date of diagnosis,
months), EEDC or EEDC-revised classification at time of diagnosis, date of death or last
known to be alive. Date of diagnosis represented the date in which the patient was informed of
his/her diagnosis.
Definitions
In this study, we compare the baseline demographic and clinical characteristics along with out-
comes (i) of patients diagnosed and followed by the tertiary referral center in the geographical
areas considered, with those (ii) of the entire ALS population recruited by the local registers
using multiple sources. Patients that make up the tertiary referral cohort were also part of the
population-based cohort for that region.
Within each region, there is a referral multidisciplinary tertiary center, which take care
exclusively to ALS patients. A patient was defined as an attendee at the tertiary referral center
Table 1. Characteristics of European registers participating in the study.
Piedmont (Italy) Puglia (Italy) Republic of Ireland Limousin (France)
PARALS SLAP Irish ALS register FRALim
Period of recruitment (years) 1996–1999 1998–1999 1996–1999 2000–2013
Population 4,225,023 4,034,132 3,626,087 741,082
Person-years 16,900,092 8,068,264 14,504,348 10,004,607
Geographical coverage (km2) 25,400 19,345 70,280 19,942
Sources of case ascertainment
ALS tertiary referral center X X X X
Neurologists X X X X
Other specialists in the field
(neurophysiologists,
neurosurgeons, pathologists)
X
Primary care physician X
Hospital discharge data X X X
Heath insurance X
Local charitable
Organization/ALS association
X X
 Population for Ireland in 1996 (http://www.cso.ie/en/census/census1996reports/census1996principaldemographicresults/), Population for Piedmont and Puglia in
2000 (http://demo.istat.it/ric/index_e.html), Population for Limousin in 2011 (http://www.insee.fr/fr/themes/detail.asp?ref_id=estim-pop&reg_id=99)
https://doi.org/10.1371/journal.pone.0195821.t001
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if he/she was traced on more than one occasion [21, 22]. These centers were located at the ALS
Regional Expert Center, University of Turin, Piedmont, in the ALS Clinic in Bari, Puglia, the
Motor Neuron Clinic at Beaumont Hospital, Dublin, Ireland, and the ALS Expert Center of
Limoges teaching hospital.
Statistical analysis
Patient baseline characteristics were reported as frequency (percentage) and mean with stan-
dard deviation for categorical and continuous variables, respectively. Survival analysis was per-
formed using Kaplan-Meier analysis where day 0 was the date of diagnosis and the primary
endpoint was tracheotomy-free survival for Italian and Irish cohorts (date of last follow-up of
patients was July 2014) and overall survival for the French cohort (date of last follow-up of
patients was November 2014).
Differences between each referral center and its corresponding registry were assessed using
the Student’s T-test for continuous variables and the Pearson χ2 test for categorical variables.
In these comparisons, the assumption is that the means and the frequencies of the registries
are the true values of the whole target population (when an expected frequency is zero, it is
approximated to a number slightly different from zero to avoid computation problems).
A p-value of 0.05 was assumed to be the threshold for statistical significance.
Statistical analyses were performed using SPSS software (version 12.0.1, SPSS Inc, Chicago,
IL), SAS v9.3 (SAS Institute, Cary, NC), R (v 3.3.1) and Rstudio (v 1.0.153). We complied with
the Strobe Guidelines [23].
Ethical considerations
The study was approved by Ethics Committee of “Policlinico Bari” and each site had an inde-
pendent approval of the population-based registry of the region or nation (for Ireland).
Results
During the four-year study period between January 1, 1996 and December 31, 1999, 584 resi-
dents of Piedmont and 335 Irish residents were diagnosed as having suspected, possible, prob-
able, or definite ALS according to EEDC. There were 130 ALS cases diagnosed in the
population of Puglia during the two-year period January 1, 1998 to December 31, 1999. Finally,
there were 322 cases diagnosed as having possible, probable, probable laboratory supported or
definite EEDC-revised ALS during the fourteen-years period January 1, 2000 to July 31, 2013
in Limousin. These four groups represent the population-based cohorts used in this study.
Of these, 241 patients from Piedmont (41.3%) routinely attended the multidisciplinary ter-
tiary referral center at the University of Turin, 84 patients from Puglia (64.6%) attended the
tertiary referral center at the University of Bari, 222 Irish residents (representing 66.3% of the
Irish ALS population) attended the ALS clinic in Dublin and 273 patients from Limousin
(84.8%) attended the tertiary referral center from the teaching hospital of Limoges. These four
groups represent the tertiary referral center cohorts used in this study.
Demographics and clinical features of the population-based cohorts and the corresponding
tertiary referral-based cohorts are shown in Table 2.
There were no statistically significant differences between the overall ALS population-based
cohorts and the corresponding ALS tertiary center cohorts, except for the Piedmont.
However, patients attending a tertiary referral center were younger than the corresponding
population cohort. This difference in average age at diagnosis was most marked in Piedmont,
where patients attending the ALS referral center were an average of 2.4 years younger than the
overall Piedmont ALS population (p = .001). The corresponding differences were 1.6 years for
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Puglia (p = .240), 1.1 year for Limousin (p = .189), and 0.8 years for Ireland (p = .345) but not
significant. Male percentages appeared similar between ALS population and ALS referral
cohort in Ireland, Piedmont and Limousin. As for Puglia, despite the non-significance (p =
.329) there was a greater difference in the male percentage between the ALS population
(62,3%) and the referral-cohort (57,1%).
The rate of fALS was reportedly higher in Irish and French as compared to the Italian
cohorts. Patients with familial disease were more likely to attend the ALS centers in Dublin,
Turin and Limoges.
No significant differences in site of symptom onset between ALS population and referral-
cohort were found.
Nevertheless, it is possible to notice that with the exception of the French cohort, patients
with bulbar-onset ALS were overall underrepresented in referral centers. In the Irish ALS
referral center, 35.3% of patients described dysphagia or dysarthria as their initial symptoms
compared 38.5% in the Irish ALS population. The same trend was observed in Italy.
Table 2. Demographics and clinical features of the Irish, Italian and French ALS population cohorts and the corresponding tertiary referral cohorts.
Piedmont (Italy) Puglia (Italy) Republic of Ireland Limousin (France)
PARALS
Register
Turin ALS SLAP Bari ALS Irish ALS Dublin ALS FRALim Limoges ALS
Register Referral
center
Register Referral
center
Register Referral
center
Register Referral
center
(n = 584) (n = 241;
41.3%)
p
value
(n = 130) (n = 84;
64.6%)
p
value
(n = 335) (n = 222;
66.3%)
p
value
(n = 322) (n = 273;
84.8%)
p
value
Mean age at
diagnosis (SD)
65.3 62.9 (11.7) 0.001 62.3 60.7 (12.4) 0.240 64.0 63.2 (12.6) 0.345 68.7 67.8 (11.3) 0.189
Male cases 322 (55.1%) 133 (55.1%) 0.987 81
(62.3%)
48 (57.1%) 0.329 182
(54,3%)
122 (54,9%) 0.851 182
(56,5%)
154 (56,4%) 0.970
Familial ALS
cases
11 (1.9%) 7 (2.9%) 0.243 2 (1.5%) 1 (1.2%) 0.795 11 (3.3%) 8 (3.6%) 0.789 22 (6.8%) 21 (7.7%) 0.573
Site of
symptom
onset:
0.812 0.996 0.552 0.803
Bulbar 216 (37.0%) 82 (34.0%) 34
(26.2%)
21 (25.0%) 125
(38.5%)
77 (35.3%) 99 (30.9%) 87 (32.0%)
Limb 364 (62.3%) 157 (65.1%) 96
(73.8%)
63 (75.0%) 171
(52.6%)
125 (57.3%) 221
(69.1%)
185 (68.0%)
Respiratory 4 (0.7%) 2 (0.9%) 0 0 0 0 0 0
Generalized 0 0 0 0 29 (8.9%) 16 (7.3%) 0 0
Mean
diagnosis
delay (SD)¶
10.5 10.3 (9.0) 0.730 14.2 14.6 (14.0) 0.794 9.3 9.0 (11.3) 0.741 11.9 11.9 (12.4) 1
Median
survival from
onset
(months)†
28.9 33.3 - 27.2 25.6 -
Median
survival from
diagnosis
(months)†
16.0 18.3 - 15.6 17.3 -
 Data was missing for 10 patients in the Irish ALS population (5 patients attending Dublin ALS referral center), 2 patients in the Limousin ALS population (1 patient
attending the Limoges ALS referral center)
¶ data was missing for 119 patients in the Irish ALS population (67 patients attending Dublin ALS referral centre)
† Data was missing for 3 patients attending the Limoges ALS referral center
https://doi.org/10.1371/journal.pone.0195821.t002
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While diagnostic delay appeared different among countries (e.g. 9.3 months in Ireland, 14.2
months in Puglia, 11.9 months in Limousin and 10.5 months in Piedmont) there was no signif-
icant difference between overall ALS populations and ALS referral cohorts.
Finally, patients attending the referral centers tended to live longer than the general ALS
populations even if not significant. As compared to the median survival for the ALS popula-
tion-based cohort, the increases for the corresponding referral cohorts were of 11% in Limou-
sin, 15% in Piedmont and 14% in Ireland. There was no relevant difference in Puglia.
Discussion
Main results
In this paper, we analyzed data from four large population-based epidemiological ALS studies
and determined that the clinical features and survival patterns of patients attending ALS refer-
ral centers tended to differ from the general ALS population. Patients referred to ALS centers
tended to be younger (ranging from 0.8 to 2.4 years on average), less likely to present a bulbar
onset, had a higher proportion of familial antecedents and a longer survival (ranging from
11% to 15%) as compared to the underlying ALS population. This study suggests a possible
trend to referral bias in cohorts of ALS patients drawn solely from referral or hospital data-
bases. We are obviously aware of the fact that it is difficult to draw conclusions on the general
referral bias extent because of the between-population variability. The sources of this pheno-
typic variability are several and often unknown but one is surely genotype [19, 24].
Difference between centers
The proportion of ALS patients attending referral centers varied from 41.3% in Piedmont to
85.0% in France, indicating indirectly the proportion of patients referred to primary and sec-
ondary care is still relatively large in some regions of Italy.
A number of interdependent factors influence the referral pattern to a particular ALS center
including (i) organization of ALS care at the national level, (ii) local healthcare infrastructure,
willingness to refer to a more specialized care among local neurologists and physicians, geo-
graphical location, (iii) sociocultural and socioeconomic level of the patients, and (iv) physical
capacity for patients to go to ALS referral center. In this case, the distance to the referral center
becomes relevant even in the early phase of the disease especially for more severe or older
cases.
Overall, these factors determine the proportion of the general ALS population receiving
their care at the specialist ALS clinic. At the time of data collection, almost two-thirds of all
ALS patients in Ireland and Puglia and five-sixths in Limousin attended the regional ALS cen-
ter and consequently the clinical features of these referral cohorts were the most similar to the
corresponding ALS populations. In contrast, less than half of ALS patients recruited in the
population-based registry in Piemonte, attended the Turin ALS center. Hence, our data sug-
gests that it is not possible to estimate the extent of a referral bias in a clinic without first per-
forming a direct comparison with the ALS population within the geographic area of interest.
Selection bias and time
The proportion of patients with ALS in the population who were referred to the ALS centers
tended to increase with time in our study. This reflected in an increasing similarity between
referral and population-based samples. However, although one may expect that in the future,
patients seen in ALS centers will be a representative sample of the underlying ALS population,
the apparent reduction of selection bias in our study may be related to the fact that referral
Referral bias in ALS epidemiological studies
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centers and population registries in the setting that were explored in this study are run by the
same investigators. For this reason, we expect that in geographic areas with no population reg-
istries the differences between referral patients and the underlying ALS population are proba-
bly greater. It is possible that an ALS registry increase the awareness of ALS and of possible
best pathways for cure in the population of that geographic area. The proportion over time of
subjects shifting from primary and secondary care to tertiary ALS care in the area of a new
population-bases registry is the measure of reduction of the possible bias and at the same time
of the improvement of ALS care.
Ageing issue
We showed here that younger patients have a more likely access to ALS referral centers. This is
probably related to the fact that young patients are more likely to seek highly specialized care
or to be referred to them by caring physicians [25]. Younger cohorts from ALS referral centers
might drive at least partially the differences between the overall ALS population and the ALS
referral cohorts in terms of clinical characteristics (i.e. proportion of bulbar onset cases) and
prognosis (i.e. survival) [26].
Western populations are becoming older, leading to an increase in mean age at time of ALS
diagnosis. For example, in our study mean age was comprised between 64.0 to 65.3 years for the
Irish and Italian cohorts (created before 2000), while it was 68.7 years in the French cohort (cre-
ated after 2000). We can then expect, in each site, a possible progressive rise of referral bias, in
relation with the ageing of the population (and independently from the exhaustiveness pattern
of the ALS clinic) [27]. The proportion of older people increases the number of subjects who do
not reach the multidisciplinary clinic. This is due to the characteristics of rapid serious
impairment in ALS elderly and to the trend to stay in facilities near home for elderly care.
fALS
The definition of what is a familial case is difficult and inconsistent across neurologists, including
ALS experts [28]. In a referral center, ALS specialists may be more aware of familial ALS and the
importance of different genotypes and therefore more keen in the identification of familial cases.
Population-based epidemiological studies have shown the rate of fALS to be between 1.5% and
6.5% [10, 11, 13, 14, 29], with a pooled proportion estimated at 4.7% by a meta-analysis [28],
whereas referral-based studies consistently reported rates of about 10% [30, 31]. A detailed case
control study with verification by death certification, and associated interrogation of data held in
a population-based register has suggested that the rate is up to 15% In Ireland [32].
Piedmont patients with a family history of ALS were nearly 60% more likely to be referred
to an ALS clinic. Patients with a family history are often more knowledgeable about the disease
and the healthcare resources available within their community. This patient group is also moti-
vated to seek out expert opinion concerning the genetic risk to other family members. The
phenotype of familial ALS patients may differ from that of sporadic patients in relation with
the underlying high-risk gene implicated [33]. fALS patients tend to be younger, have slower
progression rates and equal male and female incidence [34]. Though the absolute numbers are
low, a higher proportion of familial cases may influence the overall clinical characteristics of a
clinical-based cohort. Familial aggregation precise estimates are important both for genotype
prevalence and environmental exposure, especially early in life [32].
Bulbar onset
The proportion of bulbar-onset ALS patients varied considerably from one country to another,
from 38.5% in the Irish ALS cohort and 37% in Piedmont, vs. 31% in Limousin and 26% in
Referral bias in ALS epidemiological studies
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Apulia, as previously described by the EURALS Consortium [7]. Except for Limousin, referral
patients had lower proportions of bulbar-onset cases than patients from population registries.
The difference in in prevalence of bulbar phenotype across registries and clinical center may
determine the difference in prognosis across the two type of settings. The bulbar has a consid-
erable worse prognosis according to most studies (up to 16 months shorter than limb-onset
disease [35]). The site of onset and age may have profound impact on the evaluation of prog-
nosis. This has be taken into account when selecting patients for clinical trials in the process of
evaluation of new drugs in tertiary referral center. It is still not clear if this difference across
European countries is real or due to different clinical approach.
Survival
Survival varied when ALS populations were contrasted to referral cohorts.
Other studies have shown that the difference in age and type of onset are responsible of
these differences [26]. Selection of the samples due to the severity of the disease at time of diag-
nosis, tends to exclude from referral cohorts patients with unfavorable prognostic factors and
therefore shorter survival. This characteristic may hamper the validity of the data from refer-
ral-cohorts in particular on prognosis.
Previous studies in the field
Previous studies attempted to describe bias related to referral centers [36, 37]. They were criti-
cized for some design characteristics: small study size, differences in term of geographical cov-
erage between population-based and referral-based cohorts [36] or by the fact that they
compared local prevalent cases versus the populations attending a referral center [37], which
might have skewed their results [38].
Lee et al. [36] identified referred patients to be younger (57.3 vs 59.9 years), more frequently
male (63% vs 52%), with a higher proportion of fALS cases (5.0% vs 2.1%), a higher proportion
of upper extremity onset and a longer diagnostic delay (12.0 months vs 9.0 months). Interest-
ingly, they also displayed different referral patterns depending on ethnicity (5% of blacks in
the referral cohort as compared to 16% in the incident cohort), reflecting difficulties to access
of care for some population groups. Effects of unfavorable prognostic factors were stronger in
the incident cohort and characteristics of referral patients were more homogeneous. While
within the first three years survival was not dramatically different between cohorts, it was 21%
in referral cohort and 4% in incident cohort at five years. Sorenson ed al [37], based on Mayo
clinic ALS database, found a 11-month difference in survival between local patients (median
survival time 18 months) and referred patients (median survival time: 29 months, p = 0.007).
The referred patients had a 5-month delay in the first appointment to the ALS clinic, more
riluzole and non-noninvasive positive pressure ventilation prescription. No difference was
identified in terms of age, gender or bulbar onset.
The above-mentioned differences have also been identified by the few studies that
attempted to assess the efficacy of multidisciplinary care in ALS [21, 22, 39]. Comparing
patients from general neurology clinics and patients underlying multidisciplinary care (MDC),
Traynor et al. [21] found MDC patients to be younger by 5.5 years, more frequently self-
reporting as fALS cases (12.2% vs 2.7%), and bulbar-onset patients (40.8% vs 34.1%). Chiò
et al. documented a younger age for referred patients (4.2 years), but did not identify differ-
ences in terms of sex, type of onset, and diagnostic delay [23]. In both studies, referred patients,
who also had a greater access to riluzole and combination of all available strategies (increased
use of non-invasive ventilation, attention to nutrition and earlier referral to palliative referral
services [8]), displayed longer median survival times, of respectively 7.5 months and 10.0
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months. However, while the populations were different, multivariate analysis revealed an inde-
pendent effect on improvement of the survival of the multidisciplinary care, a finding which
was recently replicated [40, 41]. Notwithstanding, the evidence for its effectiveness is consid-
ered as unclear (“low and very low quality of evidence”) by the Cochrane group [42] who con-
siders the benefit for survival as “conflicting”.
Consequences for ALS research
This study provides possible evidence that patients form tertiary centers are self-selected and
may be not entirely representative of the reference ALS population. Remarkably for clinicians,
the phenotype of ALS at beginning of disease is different in some important traits between
populations [41]. Hence, the studies from clinical cohorts focusing on phenotype, prognosis or
biomarkers are likely to provide point estimates that are influenced by the setting. As recruit-
ment of ALS patients in RCT is generally based on ALS tertiary centers, this might also signifi-
cantly affect the results of experimental studies. While this issue is up to now largely
undervalued [43], we can postulate that groups of ALS patients included in RCT are younger,
less likely women, with longer diagnostic delay, more frequent spinal onset and fALS [44].
This selection, favoring the subjects with better prognosis, could at least partially help to
explain the negative results of ALS trials.
Our study showed some differences when contrasting patients from different registries.
Some difference may be real but could be also due to subtle differences both in populations
and in practice across different centres in Europe. Variation of ALS clinical presentation and
survival between Northern, Western and Southern European sub-continents was recently
explored and discussed [41].
The reported differences cannot be explained solely by the small differences in age at onset
and other known and unknown factors may play a role. This finding, implies the need to con-
sider the country of origin, a possible surrogate of the underlying genotype, as an important
possible modifier of the effects of any experimental treatment.
An additional limitation of our study is the lack of data on percentage of diagnoses not con-
firmed by neurologists in the tertiary centers or in the registry. The percentage of change in
ALS diagnosis is 7% after three years in European registries [45]. For further studies it would
be interesting to analyse the degree of agreement between diagnosis in different care settings.
In conclusions the extent and possible causal components of recruitment in clinical series
from referral centers need to be carefully examined and contrasted possibly with the results of
population-based studies in the same geographic area. The presence of a registry especially if
stable over several years [46] may enhance the referral of ALS patients to tertiary center of the
area over time. The ongoing population-based registries in Europe may add useful information
on results and methods of clinical ALS studies enhancing the quality of this process in tertiary
referral centers [8, 46].
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